HCL Technologies Denmark Aps
HCL Technologies Denmark Aps is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was conducted in 12 countries: Austria, Canada, Germany, Hungary, India, Ireland, Japan, Malaysia, Poland, Thailand, the United Kingdom, and the United States.
These findings describe the trial, not the service provider’s performance or responsibility.
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
Sponsor Novo Nordisk A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination with Insulin Aspart, in Adults with Type 1 Diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5
Sponsor Novo Nordisk A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for HCL Technologies Denmark Aps?
The 2026-10-09 snapshot links HCL Technologies Denmark Aps to 9 distinct CTIS trials. Recorded services include eDiary Hardware, Logistics and Helpdesk Supplier, e-PID helpdesk, eDiary helpdesk, HCL Tech, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for HCL Technologies Denmark Aps?
The most frequently recorded therapeutic areas are Endocrinology, Metabolic Disorders, Cardiology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to HCL Technologies Denmark Aps conducted?
The linked trials record locations in 21 countries, including Poland, Germany, Italy, Czechia, Spain. These are trial locations, not confirmed office locations or countries where HCL Technologies Denmark Aps delivered services.
What can this page tell me about HCL Technologies Denmark Aps's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under HCL Technologies Denmark Aps. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- HCL Technologies Denmark ApS
- HCL Technologies Denmark Aps